Loading…
Liquid chromatographic determination of unbound flecainide in therapeutic drug monitoring
An assay method was developed for determining unbound flecainide in serum by reversed phase-high performance liquid chromatography (HPLC). Serum water including unbound flecainide was separated by ultrafiltration of the serum sample and subjected to C 18-cartridge extraction followed by HPLC analysi...
Saved in:
Published in: | Journal of pharmaceutical and biomedical analysis 2003-06, Vol.32 (2), p.375-380 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | An assay method was developed for determining unbound flecainide in serum by reversed phase-high performance liquid chromatography (HPLC). Serum water including unbound flecainide was separated by ultrafiltration of the serum sample and subjected to C
18-cartridge extraction followed by HPLC analysis. The recovery of flecainide from serum water was greater than 93%. The coefficient variations for intra- and inter-day assay of flecainide were smaller than 2.4 and 3.7%, respectively. We applied the method to determining unbound flecainide in serum samples collected from 20 patients receiving oral flecainide (150–300 mg/day) for tachyarrhythmia. Total and unbound concentrations for serum flecainide were 403.5±200.8 ng/ml and 180.2±95.0 ng/ml, respectively. Linear relationship was observed between total and unbound concentrations (
r=0.978,
P |
---|---|
ISSN: | 0731-7085 1873-264X |
DOI: | 10.1016/S0731-7085(03)00130-4 |